




RealRate

PHARMACEUTICAL 2022

DMK Pharmaceuticals Corp
Rank 366 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of DMK Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DMK Pharmaceuticals Corp compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 29% points. The greatest weakness of DMK Pharmaceuticals Corp is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 83% points.

The company's Economic Capital Ratio, given in the ranking table, is 181%, being 94% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	35,204
Cost of Goods Sold	6,872
Intangible Assets	0
Liabilities, Current	11,223
Liabilities, Non-Current	343
Other Assets	760
Other Compr. Net Income	0
Other Expenses	0.80
Other Liabilities	850
Other Net Income	-13,758
Other Revenues	2,209
Property and Equipment	2,335
Research and Development	11,262
Selling, General and Administrative Expense	16,144

Output Variable	Value in 1000 USD
Assets	38,298
Liabilities	12,415
Expenses	34,279
Revenues	2,209
Stockholders Equity	25,883
Net Income	-45,828
Comprehensive Net Income	-45,828
BaseVar	50,479
ECR before Limited Liability	42%
Economic Capital Ratio	181%